Therapy Areas: Cardiovascular
AstraZeneca reports on voting rights and capital
3 January 2018 -

AstraZeneca Plc (STO: AZN) reported on Tuesday that as of 31 December 2017, the issued share capital of the company with voting rights was 1,266,221,605 ordinary shares of USD0.25.

Also, no shares are held in treasury. Therefore, the total number of voting rights in AstraZeneca Plc was 1,266,221,605.

According to the company this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca Plc under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca is a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular & Metabolic Diseases and Respiratory. It is also selectively active in the areas of autoimmunity, neuroscience and infection.



Related Headlines